Brand Cialis $4,800/yr. Tadacip $60/yr. Same molecule, 80x markup — here's where it goes.

Brand Cialis 5mg daily at a US retail pharmacy costs $70-100 per pill. The same 5mg tadalafil routed through us — Cipla's Tadacip 5mg — costs $0.50-1.00.

Same molecule. Same FDA-bioequivalent tadalafil. Cipla is the Indian generics giant whose USFDA-inspected facilities supply most of the LMIC HIV antiretroviral lane and ship into 80 countries — the same kind of WHO-prequalified manufacturer your CVS pharmacy buys from when it stocks generic tadalafil.

The price ratio is roughly 80x.

That number doesn't come from one thing. It comes from six. Brand premium, DTC marketing, FDA pathway recovery, wholesale chain, retail dispensing, insurance friction. Tadacip skips five of the six. The CVS generic — the legitimate US-FDA-approved generic tadalafil sitting on the same pharmacy shelf as Cialis brand — skips most but not all.

Here's the cost stack, layer by layer, with what each one actually pays for.

Honest math first.

Brand-vs-LiberaCure, the two lanes the 6-layer teardown actually compares:

The 80x ratio is brand-vs-Tadacip 180-pack. Brand-vs-Tadacip 30-pack is closer to 26x. The Cialis brand price is the line that funded the entire stack until the US patent expired in 2017. Indian generic tadalafil existed earlier under the pre-2005 process-patent regime there, but the US generic and US telehealth lanes both opened up only after the US patent cliff. The patent expiring is what created the right-side spread for US patients.

Read the layer breakdown with that in mind. The biggest layer you're paying isn't the molecule. It's the chain.

Where the mid-tier US lanes land (separate question, separate section below)

For US patients who can't or won't use personal-import, the molecule still has cheaper paths than brand cash:

The mid-tier lanes carve different slices off the brand premium and the dispensing chain. Telehealth (Hims, Roman) compresses the brand premium and the in-person visit cost but keeps a subscription markup. CVS retail cash without insurance bypasses the PBM rebate engineering but keeps the retail dispensing fee. TRT clinic bundles hide tadalafil inside a bigger subscription. None of these touches the wholesale chain or Indian-pharmacy labor cost the way personal-import does.

The 6-layer teardown below is the brand-vs-Tadacip case. The mid-tier lanes pay subsets of layers 4-6 (wholesale, retail, insurance) — full breakdown in the Roman pricing trap article and the TRT clinic markup piece.

Layer 1 — Brand premium (~$28-35 of every $80 brand pill)

Lilly's Cialis NDA (FDA approval 2003) cost roughly $1-2 billion when you amortize the failed candidate molecules across the program. Lilly recovers that across the patent window. Until 2017, the patent was the moat.

What "brand premium" actually pays for, when you peel it apart:

• R&D recovery — phase 1-3 trial cost industry-typical for an ED-class small molecule runs $300-500M; the tadalafil-specific figure isn't publicly broken out in Lilly's 10-K. Plus the 9-of-10 candidate molecules that failed.
• Patent-window profit margin — Lilly's gross margin on branded ED pharmaceuticals at peak was in the 75-85% range typical of blockbuster brand drugs (Cialis-specific margin isn't disclosed standalone in Lilly's segment reporting). A meaningful chunk of every $80 brand pill is shareholder return on capital that took risk in 2002.
• Brand equity — the word "Cialis" itself, after twenty years of NFL spots and "two bathtubs" billboards, carries lift even off-patent. Some patients still pay for the name.

The patent expired in the US in 2017. The legal moat collapsed. The brand premium didn't disappear immediately — Lilly still gets paid by patients who don't comparison-shop and by insurance plans that haven't switched their formulary to generic-first. That's why "brand Cialis at CVS, cash, 2026" is still $70-100/pill in 2026.

It's a residual brand tax on people who didn't know the molecule went off-patent.

Tadacip pays zero of this layer. Cipla didn't run the NDA trial. Cipla launched Tadacip in the early-to-mid 2000s under India's pre-2005 process-patent regime — meaning the molecule was reverse-engineerable in India before TRIPS-aligned product patents took effect. Cipla pays manufacturing and a small Indian regulatory amortization.

Layer 2 — DTC marketing (~$8-12 per brand pill)

Direct-to-consumer pharmaceutical marketing is legal in two countries: the United States and New Zealand. Everywhere else, it's prohibited or sharply restricted.

That's why Cialis was the NFL Sunday spend that made "ED" a brand category in the US between 2005 and 2017. Roughly 10-15% of the brand price is the marketing budget that keeps Cialis the word people Google when they want a name for the problem.

The CVS generic doesn't pay this layer. The generic manufacturer didn't spend on Sunday spots. They show up on the formulary because the molecule went off-patent and CVS needs a low-cost SKU.

Tadacip doesn't pay this layer. Cipla doesn't run TV ads in the US. They run a generics catalog into 80 countries on a totally different operating model.

Layer 3 — FDA NDA pathway amortization (~$8-10 per brand pill)

This is the layer most articles conflate with Layer 1. They're related but different.

Layer 1 is "Lilly recovers the cost of developing this molecule." Layer 3 is "Lilly recovers the cost of running it through the FDA NDA approval process specifically." A new molecular entity NDA costs $50-150M in regulatory expenses alone — separate from the trial science. Document preparation, FDA back-and-forth, post-approval surveillance commitments, the whole bureaucratic stack.

The CVS retail generic pays a small ANDA pathway cost — abbreviated new drug application, roughly $1-3M. That's why generics are cheap. The hard regulatory lift was already done by Lilly. Generic manufacturers piggyback on the existing approval and prove bioequivalence.

Tadacip pays an Indian regulatory pathway (CDSCO — Central Drugs Standard Control Organisation) plus the WHO-GMP audit infrastructure that lets Cipla ship into LMIC programs. Total amortized cost, much smaller than ANDA.

Layer 4 — Wholesale distribution chain (~$12-16 per brand pill)

Three middlemen sit between Lilly's manufacturing line and your hand.

Pharmacy benefit manager (PBM). Express Scripts, CVS Caremark, OptumRx. These are the three that handle ~80% of US prescription volume. They negotiate "rebates" with manufacturers — a Lilly list price of $80 pays $50 to the PBM after rebate, but the PBM keeps a chunk and passes some to the insurance plan. The patient cash price stays $80.

(In plain English: a PBM is a middleman wholesaler between your insurance plan and your pharmacy. Lilly sets a list price of $80, then quietly hands the PBM a $30 "rebate" on the back end — kickback by another name. Your insurer claims credit for negotiating it. You at the cash counter still see $80.)

Wholesaler. AmerisourceBergen / McKesson / Cardinal Health. These three handle ~90% of US pharmaceutical distribution. Typical markup is 2-5% of acquisition cost.

Retail pharmacy markup. CVS, Walgreens, Rite Aid markup over wholesale.

Each of these layers exists for legitimate operational reasons. They also each take their cut. The aggregate distribution markup on a brand drug is typically 15-25% of the retail price.

The CVS retail generic compresses this. The wholesaler still takes a cut, the pharmacy still marks up, but the PBM rebate game is much smaller because the molecule is generic and the rebates aren't worth fighting over.

Tadacip skips the entire US distribution chain. Cipla's product flows from a Goa or Indore plant through an Indian wholesale channel into a licensed personal-import pharmacy. That pharmacy handles fulfillment direct to international patients. There's no PBM, no AmerisourceBergen, no CVS counter.

Layer 5 — Retail pharmacy dispensing fee (~$10-15 per Rx)

When CVS dispenses a 30-day supply of any drug, there's a flat dispensing fee built into either the cash price or the insurance reimbursement. Industry-typical: $10-15 per fill (varies by pharmacy chain, region, and contract). Higher at 24-hour pharmacies, lower at high-volume mail-order operations.

This fee covers the pharmacist's time, the counting, the labeling, the brief counseling session you usually waive. Real labor, real overhead, real liability tail.

The CVS retail generic pays this layer in full. The dispensing fee is preserved across cash and insurance pathways — it pays for labor, not the molecule.

Tadacip skips this layer because there's no US retail pharmacist in the chain. The Indian licensed pharmacy fulfilling the order has a dispensing fee inside its own price, but at Indian retail pharmacy labor rates, that's roughly $0.30-0.80 per fill amortized into the per-pill cost.

Layer 6 — Insurance friction (~$8-12 per brand pill, varies)

If you have insurance, the price you see at the counter has been engineered. The list price is high so the PBM rebate looks generous. The copay structure is engineered so the plan pays more on tiers it has rebate deals for.

For Cialis specifically, most US commercial insurance plans don't cover ED medication — Medicare Part D explicitly excludes it. So a brand Cialis prescription often runs at full cash list price even for insured patients, with the patient eating the entire $80/pill.

For tadalafil generic, insurance coverage is patchy. Some plans cover with a $30-50 copay. Some require prior authorization. Some still exclude on the "lifestyle drug" carve-out.

This is why retail cash pricing matters for the uninsured tier. Walking into CVS / Walgreens / Walmart without insurance, the cash counter price for generic tadalafil 5mg lands at $150-450/mo depending on store and region — the dispensing chain stays in place even though the molecule is generic. That's the lane where most US patients without coverage actually find themselves, and it's the spread the Roman pricing trap article attacks from a different angle.

Tadacip skips this layer because there's no insurance involvement at all. It's a cash transaction outside the US insurance system.

What's actually inside each lane.

Stack the same molecule, layer by layer, dollar by dollar.

All numbers below are per-pill, with retail dispensing fees amortized across a 30-pill fill (so a $10-15 dispensing fee shows as $0.33-0.50 per pill, not the full fee).

Read this two ways.

The CVS retail generic ducked the brand premium, the DTC marketing, and the NDA amortization. It still pays the full wholesale chain (US-priced), the retail pharmacy fee, and the cash-counter spread that PBMs engineer for uninsured walk-ins.

Where the spread between CVS retail cash and Tadacip opens up: the wholesale chain (US wholesalers take a 2-5% margin per layer, three layers deep), the retail pharmacy labor cost (US wages), and the cash-counter spread for uninsured patients. That's why CVS retail cash without insurance lands at $150-450/mo, not the $10-25/mo number you see quoted in articles that assume insurance and a cash-discount coupon stack on top.

The Indian licensed pharmacy fulfilling our route prices its dispensing labor at Indian retail rates — roughly an order of magnitude lower than US retail pharmacy labor. That, plus skipping the US wholesale chain entirely, is what produces the 10-30x spread between CVS retail cash and our lane on the same molecule.

The metaphor.

Cialis brand pricing is a six-story building. Each floor adds $10-30 to the rent. The molecule itself sits in the basement at $1-2 per pill.

CVS retail generic (cash, no insurance) is the same building with the top three floors closed off — brand premium, DTC, NDA amortization all gated. You still walk through the lobby (manufacturing), the wholesale floor, and the retail dispensing floor, and you exit at $150-450/month because the lower floors are still US-priced. Mid-tier telehealth (Hims, Roman) lets you skip the in-person retail dispensing visit but charges you a subscription concierge fee on the way out.

Tadacip is a different building entirely. One floor — manufacturing plus a small Indian regulatory and logistics tail. The exit is at street level. $15-30/month at the 30-pack tier, $5-9/month at the 180-pack tier.

Same molecule arriving at different exits. The cost of each exit reflects which floors you walked through to reach it.

What to do this week.

If you're already on brand Cialis and paying retail cash:

1. Switch to generic tadalafil 5mg at any retail pharmacy — same molecule, FDA-certified bioequivalence. Cash price at CVS / Walgreens / Walmart / Costco without insurance lands at $150-450/mo depending on store and region. That alone cuts the brand premium out: ~$3,000-6,000 saved per year just by switching off the brand SKU.
2. If $150-450/mo cash retail still feels high, telehealth subscription (Hims $40-90/mo, Roman $240/mo at $8/dose) compresses the dispensing chain further by skipping the in-person visit, at the cost of a subscription markup. See the Roman pricing trap article for the auto-renewal math.

If you have a US prescription and the retail cash or telehealth price feels reasonable for your situation:

1. Stay there. Both lanes carry a US-licensed clinician relationship and US-domestic shipping that personal-import doesn't.
2. Our lane wins for you only if you don't want a prescription, are outside the US, or want larger pack sizes (90-day or 180-day supply at one shot) without monthly pharmacy trips or subscription auto-renewals.

If you don't have a US prescription, don't want one, or are outside US insurance entirely:

1. The personal-import lane is the framework that fits.
2. LiberaCure-routed Tadacip 5mg pack tiers: 30-pack $15-30 ($0.50-1.00/pill), 90-pack $27-45 ($0.30-0.50/pill), 180-pack $30-54 ($0.16-0.30/pill). The 180-pack is where the title's $60/yr figure actually lands.
3. Crypto checkout (BTC, USDT TRC-20, LTC, XMR, ETH via NOWPayments). 2-week standard lead time, 2-4 weeks with customs variance. Reship once free if tracking shows lost in transit, second reship also free, crypto refund on third failure. Email reply 24-48h ([email protected]).
4. Read the honesty page for the country-by-country personal-import legal framework before ordering.

A note on bias.

We route tadalafil orders. Be aware of that.

LiberaCure routes orders to licensed personal-import pharmacies. Tadacip and Tadaflo (both by Cipla) are the global-pharma tadalafil SKUs the export channel ships most consistently into our supply, with Modula and Forzest (Sun Pharma) and Tazzle (Dr. Reddy's) appearing as same-category equivalents when supplier inventory rotates. We also route ED-specialist tadalafil brands (Vidalista, Tadarise, Tastylia) for patients who specifically need a chewable, sublingual, or 2.5mg micro-dose. So we have a financial reason to want this article to lead you toward "give the personal-import generic lane a try."

Read this with that in mind. The 6-layer breakdown above is structurally accurate either way. The recommendation about which lane fits which patient is what I'd tell a friend, not what maximizes reorder rate.

If retail cash at $150-450/mo or a telehealth subscription at $40-90/mo is the right friction profile for you, take it. The point of laying out the six layers isn't to push you off your current lane. It's to make sure you're not paying the brand premium by accident — that's the layer with no clinical value at all.

Related reading

• Tadalafil 5-brand teardown — why global-pharma giants anchor our default
• Tadalafil daily vs PRN — the lease-versus-rental math most prescribers don't run
• Cenforce vs Viagra — the same factory question, but for sildenafil
• Hims sildenafil 99% markup — the same anatomy applied to telehealth
• TRT clinic sildenafil markup — bundle pricing as a stealth profit driver

Sources:

• FDA Cialis (tadalafil) label, NDA 21-368 (2003), patent expiration 2017, ANDA approvals 2018-2019.
• Eli Lilly and Company Annual Report 10-K, Cialis revenue and margin disclosures, 2010-2017.
• DiMasi JA et al. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ 2016;47:20-33. (NDA cost estimate ~$1-2B per approved molecule.)
• FDA Orange Book, tadalafil generic AB-rated equivalence.
• US Government Accountability Office report on PBM rebate structure, 2019.
• AmerisourceBergen, McKesson, Cardinal Health 2024 10-K filings (US wholesale market share).
• CVS Health Annual Report, 2024 (dispensing fee disclosure).
• CVS retail cash tadalafil 5mg generic pricing (no-insurance walk-in), April 2026.
• Hims & Hers tadalafil daily plan pricing, Roman / Ro pharmacy public pricing pages (ro.co), April 2026.
• AllDayChemist, InternationalDrugMart, ReliableRx, InhousePharmacy.vu Tadacip 5mg list pricing (comparable to LiberaCure's lane), April 2026.
• Cipla Ltd. company filings — USFDA-inspected facility list (Goa, Indore), WHO-GMP certificate filings.

— LiberaCure editorial. We route generic medication through licensed personal-import pharmacies. We don't dispense, prescribe, or warehouse. Read more about why.